PharmTech Drug Digest 11.20
News|Articles|October 4, 2016

Cation Exchange Resin Achieves Higher Dynamic Binding Capacity

Tosoh Bioscience adds TOYOPEARL Sulfate-650F, a strong cation exchange resin that exhibits high salt tolerance, to its process media product line.

Tosoh Bioscience, a provider of chromatographic resins for the purification of biopharmaceutical drugs in commercial manufacturing processes, introduced TOYOPEARL Sulfate-650F, a strong cation exchange resin that exhibits a high salt tolerance, for sale in the Americas. TOYOPEARL Sulfate-650F resin allows for lowered operating costs by offering higher dynamic binding capacities for IgG. This resin can achieve a dynamic binding capacity of >120 g/L of monoclonal antibody (mAb) and exhibits pressure-flow properties at 30 cm inner diameter of up to 500 cm/hr (0.2 MPa). The resin is ideal for applications performed in physiological conditions or for post-protein A removal of aggregates. According to the company, the chromatographic resin captures mAb aggregates over a wide pH range without losing its binding capacity for mAb, resulting in higher resolution between monomer and aggregates.

Source: Tosoh Bioscience


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.